Macrogenics Inc [MGNX] stock prices are up 30.07% to $17.78 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MGNX shares have gain 18.85% over the last week, with a monthly amount drifted -13.86%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Macrogenics Inc [NASDAQ: MGNX] stock has seen the most recent analyst activity on March 04, 2024, when BTIG Research reiterated its Buy rating and also boosted its price target to $24 from $12. Previously, H.C. Wainwright downgraded its rating to Neutral on February 14, 2024, and elevated its price target to $14. On December 20, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $13 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $12 on November 07, 2023. Guggenheim downgraded its rating to a Neutral. Cowen downgraded its rating to Market Perform for this stock on November 22, 2022. In a note dated November 14, 2022, BMO Capital Markets upgraded an Outperform rating on this stock and boosted its target price from $5.70 to $16.
The stock price of Macrogenics Inc [MGNX] has been fluctuating between $4.29 and $21.88 over the past year. Currently, Wall Street analysts expect the stock to reach $19.75 within the next 12 months. Macrogenics Inc [NASDAQ: MGNX] shares were valued at $17.78 at the most recent close of the market. An investor can expect a potential return of 11.08% based on the average MGNX price forecast.
Analyzing the MGNX fundamentals
The Macrogenics Inc [NASDAQ:MGNX] reported sales of 58.75M for trailing twelve months, representing a drop of -85.33%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -2.86%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.06 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.60 points at the first support level, and at 13.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.43, and for the 2nd resistance point, it is at 21.08.
Ratios To Look Out For
It’s worth pointing out that Macrogenics Inc [NASDAQ:MGNX]’s Current Ratio is 4.48. In addition, the Quick Ratio stands at 4.46 and the Cash Ratio stands at 1.8. Considering the valuation of this stock, the price to sales ratio is 18.89, the price to book ratio is 7.23.
Transactions by insiders
Recent insider trading involved Peters Jeffrey Stuart, Senior VP and General Counsel, that happened on Mar 06 ’24 when 19625.0 shares were sold. Chief Operating Officer, Risser Eric Blasius completed a deal on Mar 04 ’24 to sell 41159.0 shares. Meanwhile, SVP, CFO and Secretary Karrels James sold 30000.0 shares on Mar 04 ’24.
